The global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is projected to reach $153,320 million by 2025, registering a CAGR of 4.2% from 2018 to 2025.
The Global Autoimmune Disease Therapeutics Market size is expected to reach $149.4 billion by 2025, rising at a market growth of 4.34% CAGR during the forecast period. The autoimmune disease therapeutics market is anticipated to experience significant market growth during the forecast period due to early diagnosis of the disease, the latest launch of advanced therapy, and increased incidence of autoimmune disease. The market is witnessing a strong presence of late-stage pipeline drugs such as tocilizumab, baricitinib, olokizumab, apremilast, abatacept, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others. On the other hand, higher costs associated with sophisticated therapy are anticipated to hamper the market growth. Full Report: https://www.kbvresearch.com/autoimmune-disease-therapeutics-market/
The autoimmune disease treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 7.60% in the above-mentioned forecast period. Increasing awareness regarding healthcare sector drives the autoimmune disease treatment market. https://www.databridgemarketresearch.com/reports/global-autoimmune-disease-treatment-market
Big Market Research, Global Liver Diseases Therapeutics Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation, 2013 – 2020. Liver diseases are one of the most prevalent diseases in the world. The commercialization of variety of liver therapeutics drugs has made the treatment of these diseases possible. The report provides an in-depth intelligence about current market trends of liver diseases therapeutics market. The objective of this report is to study the demand these therapeutics in the market and to assess its growth.
The report on Biosimilar Monoclonal Antibodies by Infinium Global Research analyzes the the Biosimilar Monoclonal Antibodies Market over the period of 2017 to 2023. This report also provides detailed qualitative and quantitative analyses of the market dynamics, market size and future trends in Global Biosimilar Monoclonal Antibodies Market. It will help a lot of decision makers to develop strategies and find new opportunities in the Global markets of Biosimilar Monoclonal Antibodies.
Market Overview: Biosimilars Market Biosimilars, biological products highly similar to and interchangeable with an already approved biological product (reference product), offer cost-effective alternatives to expensive biologics. The global biosimilars market showcases robust growth prospects, driven by increasing healthcare costs, patent expirations of biologic drugs, and the need for affordable treatment options. Market analysis indicates that the biosimilars market is poised to expand at a significant CAGR of 25.3%, surging from a valuation of $5.2 billion in 2023 to an estimated $27.9 billion by 2030.
Unlock the potential of emerging markets fueling diabetes market expansion. Explore segmentation, analysis, and the growth of diabetes care devices, therapeutics, drugs, and digital management solutions in this comprehensive market report.
Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells and heal injured tissues. Sometimes, the body defense system inappropriately triggers inflammation against its own cells, resulting in incurable inflammatory autoimmune diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD).
Injectable suspensions play a vital role in modern healthcare, providing sustained release formulations of medications for various therapeutic purposes. The global market for injectable suspensions demonstrates robust growth, fueled by increasing prevalence of chronic diseases, advancements in drug delivery technologies, and growing demand for long-acting injectable formulations. According to the latest research by Persistence Market Research, the injectable suspensions market is set to witness positive growth of CAGR 8.7% during 2021-2031.
The global plasma protein therapeutics market size is expected to grow from $26.25 billion in 2022 to $28.11 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%.
According to a new market research report, ‘Global Autoimmune Treatment Market (2009–2014)’, published by MarketsandMarkets, the global autoimmune treatment market is expected to be worth US$68.81 billion by 2014, with an estimated CAGR of 12.7% from 2009 to 2014. The North American market is expected to account for nearly 42% of the total revenues.
The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market. Read Complete Report @ http://www.researchbeam.com/anti-inflammatory-therapeutics-market On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Enquire @ http://www.researchbeam.com/anti-inflammatory-therapeutics-market/enquire-about-report
Exploring Solutions in the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Idiopathic Thrombocytopenic Purpura (ITP) manifests as an autoimmune disorder typified by diminished platelet counts, heightening the risk of bleeding and bruising incidents. Within the ITP therapeutics sector, a spectrum of interventions aims to cater to patient needs, focusing on symptom management, platelet count elevation, and complication prevention.
Navigating the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Landscape Idiopathic Thrombocytopenic Purpura (ITP) denotes an autoimmune ailment characterized by diminished platelet counts, amplifying the vulnerability to bleeding episodes and bruises. The domain of ITP therapeutics encompasses multifaceted approaches to address patients' needs, striving to mitigate symptoms, elevate platelet levels, and mitigate disease-related complications.
Primary Biliary Cholangitis (PBC), previously known as primary biliary cirrhosis, is a chronic, autoimmune liver disease that primarily affects the bile ducts within the liver. This condition, characterized by the progressive destruction of the bile ducts, can lead to the accumulation of bile acids and toxins, eventually resulting in liver damage and dysfunction. The management of PBC has witnessed significant advancements in recent years, with a range of therapeutic options offering improved outcomes and enhanced quality of life for patients. This article aims to provide an insightful analysis of the evolving landscape of PBC therapeutics, highlighting the key treatments and emerging trends shaping the market. Know More- https://www.alliedmarketresearch.com/primary-biliary-cholangitis-pbc-therapeutics-market-A108539
Technavios market research analyst predicts the global protein therapeutics market to grow steadily at a CAGR of 8% during the forecast period. Increased demand for and use of monoclonal antibodies is expected to drive the growth of the protein therapeutics market as it accounts for more than half of the protein therapeutics market.
According to the latest research report by IMARC Group, The global peptide therapeutics market size reached US$ 39.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 66.1 Billion by 2028, exhibiting a growth rate (CAGR) of 9% during 2023-2028. More Info:- https://www.imarcgroup.com/peptide-therapeutics-market
According to the latest research report by IMARC Group, The global peptide therapeutics market reached a value of US$ 35.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 61.9 Billion by 2027, exhibiting a CAGR of 9.42% during 2022-2027. More Info:- https://www.imarcgroup.com/peptide-therapeutics-market
The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market. Get more details at: http://www.apacmarket.com/top-market/anti-inflammatory-therapeutics-market
Immunofluorescence is defined as the technique used to visualize structures such as intermediate-sized filaments, and utilizes light microscopy in combination with fluorescence microscope on various microbiological samples. The various microbiological samples involve study of tissues and cells. This study is ideal for clinical research on various diseases, such as therapeutics development and diagnosis.
According to the latest research report by IMARC Group, The global autoimmune disease diagnosis market size reached US$ 3.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2027, exhibiting a growth rate (CAGR) of 6.4% during 2022-2027. More Info:- https://www.imarcgroup.com/autoimmune-disease-diagnosis-market
Big Market Research, Acquired Autoimmune Hemolytic Anemia Pipeline Market Size,Share,Trends,Pipeline Review,Overview,Forecast,Insights,Analysis. Global Markets Direct’s, ‘Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2014’, provides an overview of the Acquired (Autoimmune) Hemolytic Anemia’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia, complete with comparative analysis at various stages
Looking forward, the autoimmune disease diagnosis market value is projected to reach a strong growth during the forecast period (2021-2026). More info:- https://www.imarcgroup.com/autoimmune-disease-diagnosis-market
Big Market Research, Anchor Therapeutics Product Market Size, Share, Global Industry, Growth, Trends, Forecast, Analysis, Pipeline Review 2014. Global Markets Direct’s, ‘Anchor Therapeutics, Inc. - Product Pipeline Review - 2014’, provides an overview of the Anchor Therapeutics, Inc.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Anchor Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target.
Monoclonal Antibody Therapeutics are laboratory-produced molecules that mimic the immune system's ability to fight off harmful pathogens. These therapeutics have revolutionized the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. They target specific proteins present on the surface of cells and interfere with their function, making them a highly effective and targeted treatment option.
Big Market Research, TauRx Theraoeutics Ltd. Product Market Size, Share, Global Industry, Growth, Trends, Forecast, Analysis, Pipeline Review 2014. Global Markets Direct’s, ‘TauRx Therapeutics Ltd. - Product Pipeline Review - 2014’, provides an overview of the TauRx Therapeutics Ltd.’s pharmaceutical research and development focus.
Autoimmune diseases develop when body’s immune system recognizes the healthy body cells as foreign cells, and when immune system produces auto-antibodies that attack and destroy healthy tissues in the body rather than infectious agents. The disease is the hyperactive immune response against the substances and tissues normally present in the body and these are generally caused by genetic, infectious or environmental factors. It may lead to abnormal organ growth and changes in the functions of the organs.
Big Market Research, NovaDigm Therapeutics Inc. Product Market Size, Share, Global Industry, Growth, Trends, Forecast, Analysis, Pipeline Review 2014. NovaDigm Therapeutics, Inc. - Product Pipeline Review - 2014’, provides an overview of the NovaDigm Therapeutics, Inc.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of NovaDigm Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
the global Cancer Stem Cell Therapeutics market was valued at USD 8463.9 Million in 2018 and is expected to reach USD 16839 Million by year 2026, at a CAGR of 9 %
Amyloidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Amyloidosis Therapeutics market.
Autoimmune diseases develop when body’s immune system recognizes the healthy body cells as foreign cells, and when immune system produces auto-antibodies that attack and destroy healthy tissues in the body rather than infectious agents. The disease is the hyperactive immune response against the substances and tissues normally present in the body and these are generally caused by genetic, infectious or environmental factors. It may lead to abnormal organ growth and changes in the functions of the organs.
Big Market Research, Medicago S.P.A Product Pipeline Market Size, Share, Global Industry, Growth, Trends, Forecast, Analysis, Pipeline Review 2014. Global Markets Direct’s, ‘Medicago Inc. - Product Pipeline Review - 2014’, provides an overview of the Medicago Inc.’s pharmaceutical research and development focus.
Global Autoimmune Treatment Market is expected to reach USD 50.92 billion by 2025, from USD 37.79 billion in 2017 growing at a CAGR of 3.8% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
Global PEGylated protein therapeutics market is expected to grow at a growing CAGR of 8.7% in the forecast period of 2019-2026. Increase in strategic alliances between the pharmaceuticals companies and growing adoption of PEGylated protein therapeutics are the key factors that fueling the market growth.
Big Market Research “Protein Engineering Market by Technology” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2019. Visit for more info @ http://www.prnewswire.com/news-releases/protein-engineering-market-would-grow-at-157--cagr-amid-the-period-2015-2020-521544791.html Protein Engineering Market by Technology (Rational Protein Design, Irrational Protein Design) , Product (Instrument, Services) , Protein Type (Monoclonal Antibodies, Interferon, Growth Hormone) Global Forecast to 2020 - Developing Asian countries such as the China and India are lucrative markets for protein engineering, owing to increase in R&D investment by the biologics companies in these regions.
Get a sample brochure @ http://tinyurl.com/zmc69dn The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market.
Big Market Research, Myocarditis Therapeutic Pipeline Market, Size, Share, Global Industry, Growth, Trends, Forecast, Analysis, Pipeline Review 2014. Global Markets Direct’s, ‘Myocarditis - Pipeline Review, H2 2014’, provides an overview of the Myocarditis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Next-generation antibody therapeutics refers to improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Advancements in monoclonal antibody technologies have led to the development of next-generation therapeutic antibodies with reduced functional size, greater bifunctional properties, and low immunogenicity.
GBI Research has released its latest research, “Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential”. The report provides insights into the up-and-coming trends of a portion of the acquired orphan blood disorder pharmaceutical market by examining Idiopathic Thrombocytopenic Purpura (ITP), Myelodysplastic Syndrome (MDS), Myelofibrosis (MF), Paroxysmal Nocturnal Hemoglobinuria (PNH) and Polycythemia Vera (PV) in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. View full report with TOC: http://www.reportsandintelligence.com/acquired-orphan-blood-diseases-therapeutics-to-2019-search-for-disease-modifying-drugs-central-to-unlocking-premium-pricing-potential-market
Mobile advertising has evolved beyond an experiment to become a legitimate marketing channel for mainstream advertisers. However, the mobile channels remains challenged in certain key areas such as certain industry vertical proof points and ROI. See Full Report @ bit.ly/1sUwO8P
Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response.
Big Market Research “Autoimmune Diseases Market” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2019. Visit for more info @ http://www.bigmarketresearch.com/autoimmune-diseases-in-the-us-2015-2019-market Autoimmune diseases are caused by aggravation of the immune system. Autoimmune diseases can last for months or even years. Autoimmune reactions occur when the immune system produces autoantibodies that attack and destroy healthy tissues in the body rather than infectious agents.
Get more details @ http://bit.ly/2eg7VII Global autoimmune disease diagnostics market share is undergoing rapid consolidation, and is marked by the presence of extensive mergers and acquisitions. Major players compete on the basis of price, and introduction of new technologically improved diagnostic kits in the market.
Get more details @ http://bit.ly/2eg7VII Some of the players in global autoimmune disease diagnostics market are Abbott Laboratories, Siemens Healthcare, Beckman Coulter Inc. and Quest Diagnostics.
Big Market Research | Noninvasive Cancer Diagnostics and Technologies Market | Non-invasive diagnostic is a process of identifying the disease conditions with minimal incision in body during diagnosis. The global market for diagnostic/in-vitro diagnostics valued at $49.2 billion in 2012, which shows potential for market growth, especially in chronic diseases. Non-invasive cancer diagnostics is gaining importance over conventional diagnosis due to increase in incidences of chronic cancer such as breast cancer, and lung cancer. According to American Cancer Society, there were more than 1,660,290 new cases diagnosed in 2013.
Big Market Research, iBio Inc product pipeline market Size, Share, Global Industry, Growth, Trends, Forecast, Analysis, Pipeline Review 2014. Global Markets Direct’s, ‘iBio, Inc. - Product Pipeline Review - 2014’, provides an overview of the iBio, Inc.’s pharmaceutical research and development focus.
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects joints. It is characterized by synovial inflammation and gradual bone erosion over many years, and disease progression results in stiffness and pain, especially in the hands and feet, which hinders patient mobility. Without treatment, the disease leads to joint destruction and disability. Prior to 1998, treatment options were limited to small-molecule disease-modifying therapies, such as Methotrexate (MTX), sulfasalazine and anti-malarials.